Headquartered in South San Francisco, CA Fiscal year ends December NASDAQ: SPRB sprucebio.com
Spruce Biosciences is a late-stage biopharmaceutical company focused on developing and commercializing novel therapies for neurological disorders with significant unmet medical need. The company's lead product candidate is tralesinidase alfa enzyme replacement therapy (TA-ERT), which is in late-stage development for the treatment of mucopolysaccharidoses type IIIB (MPS IIIB), also known as Sanfilippo Syndrome Type B, a devastating pediatric neurodegenerative disorder with no FDA-approved therapies. TA-ERT is administered intracerebroventricularly and has received Breakthrough Therapy Designation, Rare Pediatric Disease Designation, Fast Track Designation, and Orphan Drug Designation from the FDA, as well as Orphan Drug Designation in the European Union. The company is pursuing accelerated approval based on a surrogate biomarker endpoint and is planning a BLA submission and confirmatory clinical trial. Spruce is a pre-revenue company currently funding operations through equity financing and strategic investments. Updated
Pre-Market Stock Futures: Futures are trading modestly higher after a stunning opening to the week, as all major indices rocketed higher. The announcement of a cease-fire deal with Iran, which the…
Pre-Market Stock Futures: The futures are trading flat after a solid start to the shortened Christmas holiday week. All of the major indices finished the day higher, but with the big event…
Spruce Biosciences is a late-stage biopharmaceutical company focused on developing and commercializing novel therapies for neurological disorders with significant unmet medical need.
The Wall Street consensus 12-month price target for SPRB is $148.00.
